Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2024-03-18 00:00:00 ET · period of report 2024-03-18 · accession 0001867096-24-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-18 | 2024-03-18 | XERS | JOHNSON JOHN | Dir | M - OptEx | $1.99 | +215.6K | 751.4K | +40% | +$429.0K |
| D | 2024-03-18 | 2024-03-18 | XERS | JOHNSON JOHN | Dir | M - OptEx | $0.00 | -215.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-18 | M | A | 215,600 | $1.99 | 751,412 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-03-18 | M | D | 215,600 | $0.00 | 0 | D | $1.99 · — to 2029-11-14 | 215,600 Common Stock | (F1) The options to purchase shares of Xeris Biopharma Holdings Inc. common stock fully vested on October 5, 2021. |